PTC Therapeutics
PTCT
PTCT
180 hedge funds and large institutions have $2.2B invested in PTC Therapeutics in 2018 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 49 increasing their positions, 60 reducing their positions, and 27 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
180
Holders Change
+14
Holders Change %
+8.43%
% of All Funds
4.12%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.16%
New
42
Increased
49
Reduced
60
Closed
27
Calls
$22.3M
Puts
$31.9M
Net Calls
-$9.64M
Net Calls Change
-$10.6M
Top Buyers
| 1 |
Franklin Resources
San Mateo,
California
|
+$123M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$85.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.7M |
| 4 |
O
OrbiMed
New York
|
+$59.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$59.3M |
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$75.7M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$59.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$40M |
| 4 |
RI
RTW Investments
New York
|
-$37.5M |
| 5 |
SCM
Scopia Capital Management
New York
|
-$32.3M |
